Search
Zofenopril
go.drugbank.com/drugs/DB13166ApprovedInvestigationalZofenopril is employed as both a cardioprotective and anti-hypertensive agent. It is an angiotensin-converting enzyme (ACE) inhibitor.
Dantrolene
go.drugbank.com/drugs/DB01219ApprovedInvestigationalChemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.
Lacidipine
go.drugbank.com/drugs/DB09236ApprovedIt is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved. … It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure.
Cetirizine
go.drugbank.com/drugs/DB00341ApprovedInvestigationalCetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal
DL-Methylephedrine
go.drugbank.com/drugs/DB11278ApprovedMethylephedrine is a sympathomimetic amine that appears in various over-the-counter cough and cold medications throughout the world , , . The abuse of methylephedrine-containing medications has been reported in Japan. Methylephedrine is ...
Pipecuronium
go.drugbank.com/drugs/DB01338ApprovedInvestigationalWithdrawnPipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.
Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigational[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive
Hydroxyprogesterone caproate
go.drugbank.com/drugs/DB06789ApprovedFDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy